1
|
Ureche C, Dodi G, Șerban AM, Covic AS, Voroneanu L, Hogaș S, Sascău RA, Stătescu C, Covic A. Predictive Value of Collagen Biomarkers in Advanced Chronic Kidney Disease Patients. Biomolecules 2023; 13:biom13020389. [PMID: 36830758 PMCID: PMC9953350 DOI: 10.3390/biom13020389] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Revised: 02/16/2023] [Accepted: 02/17/2023] [Indexed: 02/22/2023] Open
Abstract
Patients with chronic kidney disease have an increased risk of all-cause death. The value of collagen biomarkers such as procollagen type I carboxy-terminal propeptide (PICP) and procollagen type III N-terminal peptide (P3NP), in end-stage renal disease (ESRD), has not yet been defined (in the literature and in clinics). The purpose of this study was to determine the potential value of these new biomarkers in the prediction of mortality in this population. Plasma PICP and P3NP levels were determined in 140 patients with ESRD, not yet on dialysis, who were followed up for 36 ± 5.3 months. During follow-up, 58 deaths were recorded (41.4%), with the majority of them being cardiovascular deaths (43, 74.13%). Using the ROC curve, the cut-off value for the prediction of mortality for PICP was 297.31 µg/L, while for P3NP, the cut-off value was 126.67 µg/L. In univariate analysis, a value of PICP above the cut-off point was associated with a fivefold increased risk of mortality (hazard ratio (HR) 5.071, 95% confidence interval 1.935-13.29, p = 0.001) and a value of P3NP above the cut-off point was associated with a twofold increased risk of mortality (HR 2.089, 95% CI 1.044-4.178, p = 0.002). In a multivariable Cox proportional hazards model, PICP values remained independent predictors of mortality (HR 1.22, 95% CI 1.1-1.31, p < 0.0001). Our data suggest that the collagen biomarker PICP is an independent predictor of mortality in ESRD patients who are not yet on dialysis.
Collapse
Affiliation(s)
- Carina Ureche
- Department of Internal Medicine, Faculty of Medicine, “Grigore T Popa” University of Medicine and Pharmacy, University Street nr 16, 700115 Iasi, Romania
- Prof. Dr. George I.M. Georgescu Institute of Cardiovascular Diseases, 700503 Iasi, Romania
| | - Gianina Dodi
- Biomedical Sciences Department, Faculty of Medical Bioengineering and Advanced Research and Development Center for Experimental Medicine, Grigore T. Popa University of Medicine and Pharmacy of Iasi, 9-13 Kogalniceanu Street, 700454 Iasi, Romania
- Correspondence:
| | - Adela Mihaela Șerban
- Niculae Stancioiu Heart Institute, Iuliu Hatieganu University of Medicine and Pharmacy, 400012 Cluj-Napoca, Romania
| | - Andreea Simona Covic
- Department of Internal Medicine, Faculty of Medicine, “Grigore T Popa” University of Medicine and Pharmacy, University Street nr 16, 700115 Iasi, Romania
- Nephrology Clinic, Dialysis, Renal Transplant Center, .I. Parhon University Hospital, 700503 Iasi, Romania
| | - Luminița Voroneanu
- Department of Internal Medicine, Faculty of Medicine, “Grigore T Popa” University of Medicine and Pharmacy, University Street nr 16, 700115 Iasi, Romania
- Nephrology Clinic, Dialysis, Renal Transplant Center, .I. Parhon University Hospital, 700503 Iasi, Romania
| | - Simona Hogaș
- Department of Internal Medicine, Faculty of Medicine, “Grigore T Popa” University of Medicine and Pharmacy, University Street nr 16, 700115 Iasi, Romania
- Nephrology Clinic, Dialysis, Renal Transplant Center, .I. Parhon University Hospital, 700503 Iasi, Romania
| | - Radu Andy Sascău
- Department of Internal Medicine, Faculty of Medicine, “Grigore T Popa” University of Medicine and Pharmacy, University Street nr 16, 700115 Iasi, Romania
- Prof. Dr. George I.M. Georgescu Institute of Cardiovascular Diseases, 700503 Iasi, Romania
| | - Cristian Stătescu
- Department of Internal Medicine, Faculty of Medicine, “Grigore T Popa” University of Medicine and Pharmacy, University Street nr 16, 700115 Iasi, Romania
- Prof. Dr. George I.M. Georgescu Institute of Cardiovascular Diseases, 700503 Iasi, Romania
| | - Adrian Covic
- Department of Internal Medicine, Faculty of Medicine, “Grigore T Popa” University of Medicine and Pharmacy, University Street nr 16, 700115 Iasi, Romania
- Nephrology Clinic, Dialysis, Renal Transplant Center, .I. Parhon University Hospital, 700503 Iasi, Romania
- Academy of Romanian Scientists, 050044 Bucharest, Romania
- Academy of Medical Sciences, 020125 Bucharest, Romania
| |
Collapse
|
2
|
Butler MGK, Ambrosi TH, Murphy MP, Chan CKF. Aging of Skeletal Stem Cells. ADVANCES IN GERIATRIC MEDICINE AND RESEARCH 2022; 4:e220006. [PMID: 36037035 PMCID: PMC9409336 DOI: 10.20900/agmr20220006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The skeletal system is generated and maintained by its progenitors, skeletal stem cells (SSCs), across the duration of life. Gradual changes associated with aging result in significant differences in functionality of SSCs. Declines in bone and cartilage production, increase of bone marrow adipose tissue, compositional changes of cellular microenvironments, and subsequent deterioration of external and internal structures culminate in the aged and weakened skeleton. The features and mechanisms of skeletal aging, and of its stem and progenitor cells in particular, are topics of recent investigation. The discovery of functionally homogeneous SSC populations with a defined cell surface phenotype has allowed for closer inspection of aging in terms of its effects on transcriptional regulation, cell function, and identity. Here, we review the aspects of SSC aging on both micro- and macroscopic levels. Up-to-date knowledge of SSC biology and aging is presented, and directions for future research and potential therapies are discussed. The realm of SSC-mediated bone aging remains an important component of global health and a necessary facet in our understanding of human aging.
Collapse
Affiliation(s)
- M. Gohazrua K. Butler
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Thomas H. Ambrosi
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| | - Matthew P. Murphy
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
- Blond McIndoe Laboratories, Division of Cell Matrix Biology and Regenerative Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester Academic Health Science Centre, Manchester, M13 9PL, UK
| | - Charles K. F. Chan
- Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
| |
Collapse
|
3
|
Estrogen for the Treatment of Low Bone Mineral Density in Anorexia Nervosa. JOURNAL OF PSYCHIATRY AND BRAIN SCIENCE 2022; 7. [PMID: 35874115 PMCID: PMC9302594 DOI: 10.20900/jpbs.20220004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Anorexia nervosa is a disorder of chronic, self-induced negative energy balance which typically results in a low body weight. Functional hypothalamic amenorrhea is an adaptive response to states of negative energy balance and chronic undernutrition. A majority of women with anorexia nervosa are amenorrheic with resultant hypoestrogenemia, and longer durations of amenorrhea are associated with lower bone mineral density in this population. In this review, we highlight studies that have investigated the effects of estrogen replacement on bone mineral density in anorexia nervosa, including prospective and randomized studies that show no benefit to treatment with oral estrogen with respect to bone mineral density in either adolescent girls or women with anorexia nervosa. We also review data from a randomized, placebo-controlled study in adolescent girls and a prospective, open-label pilot study in women with anorexia nervosa suggesting that transdermal estrogen may have beneficial effects with respect to bone mineral density in this population.
Collapse
|
4
|
Resulaj M, Polineni S, Meenaghan E, Eddy K, Lee H, Fazeli PK. Transdermal Estrogen in Women With Anorexia Nervosa: An Exploratory Pilot Study. JBMR Plus 2019; 4:e10251. [PMID: 31956852 PMCID: PMC6957987 DOI: 10.1002/jbm4.10251] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Revised: 10/29/2019] [Accepted: 11/04/2019] [Indexed: 01/10/2023] Open
Abstract
Anorexia nervosa (AN) is a psychiatric disorder characterized by self‐induced starvation, low body weight, and elevated levels of bone marrow adipose tissue (BMAT). BMAT is negatively associated with BMD in AN and more than 85% of women with AN have low bone mass and an increased risk of fracture. Although a majority of women with AN are amenorrheic, which is associated with low BMD, oral contraceptive pills, containing supraphysiologic doses of estrogen, are not effective in increasing bone mass. We performed a 6‐month, open‐label study of transdermal estradiol (0.045 mg/day) + levonorgestrel (0.015 mg/day) in 11 women with AN (mean age ± SEM: 37.2 ± 2.3 years) to investigate the effects of transdermal, physiologic doses of estrogen on BMD and BMAT in women with AN. We measured change in BMD by DXA, change in BMAT at the spine/hip by 1H‐magnetic resonance spectroscopy, and change in C‐terminal collagen cross‐links (CTX), P1NP, osteocalcin, IGF‐1, and sclerostin after 3 and 6 months of transdermal estrogen. Lumbar spine (2.0% ± 0.8%; p = 0.033) and lateral spine (3.2% ± 1.1%; p = 0.015) BMD increased after 6 months of transdermal estrogen. Lumbar spine BMAT decreased significantly after 3 months (−13.9 ± 6.0%; p = 0.046). Increases in lateral spine BMD were associated with decreases in CTX (p = 0.047). In conclusion, short‐term treatment with transdermal, physiologic estrogen increases spine BMD in women with AN. Future studies are needed to assess the long‐term efficacy of this treatment. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- Megi Resulaj
- Neuroendocrine Unit Massachusetts General Hospital Boston MA USA
| | - Sai Polineni
- Neuroendocrine Unit Massachusetts General Hospital Boston MA USA
| | - Erinne Meenaghan
- Neuroendocrine Unit Massachusetts General Hospital Boston MA USA
| | - Kamryn Eddy
- Department of Psychiatry Massachusetts General Hospital Boston MA USA.,Harvard Medical School Boston MA USA
| | - Hang Lee
- Biostatistics Center Massachusetts General Hospital Boston MA USA.,Harvard Medical School Boston MA USA
| | - Pouneh K Fazeli
- Neuroendocrine Unit Massachusetts General Hospital Boston MA USA.,Harvard Medical School Boston MA USA.,University of Pittsburgh School of Medicine Pittsburgh PA USA
| |
Collapse
|
5
|
Abstract
Anorexia nervosa, a psychiatric disease predominantly affecting women, is characterized by self- induced starvation and a resultant low-weight state. During starvation, a number of hormonal adaptations - including hypothalamic amenorrhea and growth hormone resistance - allow for decreased energy expenditure during periods of decreased nutrient intake, but these very same adaptations also contribute to the medical complications associated with chronic starvation, including low bone mass. Almost 90% of women with anorexia nervosa have bone mineral density (BMD) values more than one-standard deviation below the mean of healthy women at peak bone mineral density and this disease is associated with a significantly increased risk of fracture. Although multiple therapies have been studied for the treatment of low bone mass in anorexia nervosa, there are currently no approved therapies and few promising long-term therapeutic options. This review will outline the mediators of low bone mass in anorexia nervosa, discuss therapies that have been studied for the treatment of low BMD in this disorder, and highlight the important challenges that remain, including the differences in bone modeling in adolescents with anorexia nervosa as compared to adults, necessitating that potential therapies be tested in these two populations separately, and the paucity of long-term therapeutic strategies for treating bone loss in this disorder.
Collapse
Affiliation(s)
- Pouneh K Fazeli
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA
| |
Collapse
|
6
|
Fazeli PK, Klibanski A. Effects of Anorexia Nervosa on Bone Metabolism. Endocr Rev 2018; 39:895-910. [PMID: 30165608 PMCID: PMC6226604 DOI: 10.1210/er.2018-00063] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2018] [Accepted: 08/21/2018] [Indexed: 01/14/2023]
Abstract
Anorexia nervosa is a psychiatric disease characterized by a low-weight state due to self-induced starvation. This disorder, which predominantly affects women, is associated with hormonal adaptations that minimize energy expenditure in the setting of low nutrient intake. These adaptations include GH resistance, functional hypothalamic amenorrhea, and nonthyroidal illness syndrome. Although these adaptations may be beneficial to short-term survival, they contribute to the significant and often persistent morbidity associated with this disorder, including bone loss, which affects >85% of women. We review the hormonal adaptions to undernutrition, review hormonal treatments that have been studied for both the underlying disorder as well as for the associated decreased bone mass, and discuss the important challenges that remain, including the lack of long-term treatments for bone loss in this chronic disorder and the fact that despite recovery, many individuals who experience bone loss as adolescents have chronic deficits and an increased risk of fracture in adulthood.
Collapse
Affiliation(s)
- Pouneh K Fazeli
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
| | - Anne Klibanski
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
7
|
Hiemer B, Krogull M, Bender T, Ziebart J, Krueger S, Bader R, Jonitz-Heincke A. Effect of electric stimulation on human chondrocytes and mesenchymal stem cells under normoxia and hypoxia. Mol Med Rep 2018; 18:2133-2141. [PMID: 29916541 PMCID: PMC6072227 DOI: 10.3892/mmr.2018.9174] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2017] [Accepted: 04/30/2018] [Indexed: 12/22/2022] Open
Abstract
During joint movement and mechanical loading, electric potentials occur within cartilage tissue guiding cell development and regeneration. Exposure of cartilage exogenous electric stimulation (ES) may imitate these endogenous electric fields and promote healing processes. Therefore, the present study investigated the influence of electric fields on human chondrocytes, mesenchymal stem cells and the co-culture of the two. Human chondrocytes isolated from articular cartilage obtained post-mortally and human mesenchymal stem cells derived from bone marrow (BM-MSCs) were seeded onto a collagen-based scaffold separately or as co-culture. Following incubation with the growth factors over 3 days, ES was performed using titanium electrodes applying an alternating electric field (700 mV, 1 kHz). Cells were exposed to an electric field over 7 days under either hypoxic or normoxic culture conditions. Following this, metabolic activity was investigated and synthesis rates of extracellular matrix proteins were analyzed. ES did not influence metabolic activity of chondrocytes or BM-MSCs. Gene expression analyses demonstrated that ES increased the expression of collagen type II mRNA and aggrecan mRNA in human chondrocytes under hypoxic culture conditions. Likewise, collagen type II synthesis was significantly increased following exposure to electric fields under hypoxia. BM-MSCs and the co-culture of chondrocytes and BM-MSCs revealed a similar though weaker response regarding the expression of cartilage matrix proteins. The electrode setup may be a valuable tool to investigate the influence of ES on human chondrocytes and BM-MSCs contributing to fundamental knowledge including future applications of ES in cartilage repair.
Collapse
Affiliation(s)
- Bettina Hiemer
- Department of Orthopaedics, Biomechanics and Implant Technology Research Laboratory, Rostock University Medical Centre, D‑18057 Rostock, Germany
| | - Martin Krogull
- Department of Orthopaedics, Biomechanics and Implant Technology Research Laboratory, Rostock University Medical Centre, D‑18057 Rostock, Germany
| | - Thomas Bender
- Department of Orthopaedics, Biomechanics and Implant Technology Research Laboratory, Rostock University Medical Centre, D‑18057 Rostock, Germany
| | - Josefin Ziebart
- Department of Orthopaedics, Biomechanics and Implant Technology Research Laboratory, Rostock University Medical Centre, D‑18057 Rostock, Germany
| | - Simone Krueger
- Department of Orthopaedics, Biomechanics and Implant Technology Research Laboratory, Rostock University Medical Centre, D‑18057 Rostock, Germany
| | - Rainer Bader
- Department of Orthopaedics, Biomechanics and Implant Technology Research Laboratory, Rostock University Medical Centre, D‑18057 Rostock, Germany
| | - Anika Jonitz-Heincke
- Department of Orthopaedics, Biomechanics and Implant Technology Research Laboratory, Rostock University Medical Centre, D‑18057 Rostock, Germany
| |
Collapse
|
8
|
Tommasi M, Bacciottini L, Benucci A, Brocchi A, Passeri A, Saracini D, D'Agata A, Cappelli G. Serum Biochemical Markers of Bone Turnover in Healthy Infants and Children. Int J Biol Markers 2018; 11:159-64. [PMID: 8915711 DOI: 10.1177/172460089601100304] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Serum osteocalcin (OC), bone alkaline phosphatase (BAP), carboxyterminal propeptide of type I procollagen (PICP), carboxyterminal telopeptide of type I collagen (ICTP), parathyroid hormone (PTH) and 1,25 dihydroxyvitamin D [1,25(OH)2D] were measured in 241 normal infants and children (134 males and 107 females aged 1.9 months-14 years, 1.8 months-12 years, respectively). Regarding the analysis of data for children above 2 yrs, we chose data with the following normalization: data/body surface x standard body surface, to eliminate biological variations not exclusively related to chronological age. The increase in serum OC occurred at the expected age of growth spurts in both sexes: in the first year of life OC values (mean ± SD) were 82.6 ±34.3 and 60.2 ± 32.9 OC ng/ml in males and females, respectively; during puberty, peak values occurred at the age of 10–12 yrs in girls (76.6 ± 25.8) and at the age of 12–14 yrs in boys (113 ± 48.3). Furthermore, significant positive correlations with age were found for males from 2 to 14 yrs (p < 0.00001) and for females from 2 to 12 yrs (p < 0.001). Elevated levels of BAP occurred in the first year, 70.4 ± 28.2 and 71.8 ± 28.5, and in the second year, 69.4 ± 26.7 and 67.4 ± 33.8 ng/ml, for males and females, respectively. For children older than 2 yrs, a positive correlation with age (p < 0.01) was found for females only, with a peak value of 67.2 ± 13.9 at the age of 10–12 yrs. For ages 2–14 yrs the reference values (mean ± 2SD) were 15.5 – 90.3 and 17.2 – 95.2 ng/ml for males and females, respectively. The highest PICP levels (1354 ± 680 ng/ml in males and 1041 ± 766 in females) were observed in infants less than 1 year of age, decreasing by about 60% at the age of 2. There was no significant change in serum PICP for children older than 2 yrs with values covering a range (mean ± 2SD) of 52 – 544 and 18 – 546 ng/ml in males and females, respectively. Similarly, the highest ICTP values were seen in infants younger than 1 year (29.7 ± 11.7 and 29.5 ± 20.1 ng/ml in males and females, respectively). In the ages from 2 to 14 yrs there did not seem to be any systematic age-correlated changes, with values covering a range (mean ± 2SD) of 6.06 – 24.5 in boys and 6.84 – 22.9 ng/ml in girls. Serum PTH concentrations (mean ± SD) in infancy were 27.2 ± 19.3 pg/ml for males and 25.8 ± 10.8 for females. Normal ranges (mean ± 2SD) in the older group were 5.77 – 53.1 and 6.71 – 57.3 pg/ml for males and females, respectively. Serum 1,25(OH)2D presented values of 47.3 ± 28.1 and 38.7 ± 18.2 pg/ml under 2 yrs for males and females, respectively. The ranges (mean ± 2SD) in children above 2 yrs were 9.5 – 101 pg/ml in boys and 10.9 – 88.4 in girls. The results of this study contribute to the establishment of reference values in normal children for these biochemical assays; these reference values are needed when the above biological markers will be applied in the monitoring of metabolic bone diseases.
Collapse
Affiliation(s)
- M Tommasi
- Department of Pathophysiology, University of Florence, Italy
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Seo WY, Kim JH, Baek DS, Kim SJ, Kang S, Yang WS, Song JA, Lee MS, Kim S, Kim YS. Production of recombinant human procollagen type I C-terminal propeptide and establishment of a sandwich ELISA for quantification. Sci Rep 2017; 7:15946. [PMID: 29162919 PMCID: PMC5698462 DOI: 10.1038/s41598-017-16290-9] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/18/2017] [Accepted: 11/10/2017] [Indexed: 12/26/2022] Open
Abstract
Procollagen type I carboxy-terminal propeptide (PICP), derived from type I procollagen, has been identified as an indicator of type I collagen synthesis in bone matrix formation and skin recovery. PICP is a heterotrimeric glycoprotein consisting of two α1 chains (PICPα1) and one α2 chain (PICPα2). Here, we report the recombinant expression of human PICP using a mammalian expression system. Co-expression of PICPα1 and PICPα2 in HEK293F cells resulted in the production of functional PICP in the correctly assembled heterotrimeric form. Using the recombinant PICP as an antigen, we isolated PICP-specific human monoclonal antibodies from phage-displayed antibody libraries and raised rabbit polyclonal antibodies. Using those antibodies, we then developed a sandwich ELISA for PICP with a limit of detection of 1 ng/mL and a measurable range of 1-640 ng/mL. Both intra- and inter-assay imprecision values were <10%. For measuring PICP levels in human fibroblast cellular extracts and culture supernatants and a human serum, the developed ELISA kit displayed comparable performance to that of a commercialized kit. Our results provide an efficient production strategy for recombinant PICP, facilitating the generation of PICP-specific antibodies and development of PICP sandwich ELISA, with potential use in clinical diagnosis of serum samples and testing of cosmeceutical ingredients in fibroblast cell cultures.
Collapse
Affiliation(s)
- Woo-Young Seo
- Medicinal Bioconvergence Research Center, Seoul National University, Suwon, 16229, Korea
| | - Jeong-Ho Kim
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Korea
| | - Du-San Baek
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Korea
| | - Su-Jung Kim
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Korea
| | - Sujin Kang
- Medicinal Bioconvergence Research Center, Seoul National University, Suwon, 16229, Korea
| | - Won Suk Yang
- Medicinal Bioconvergence Research Center, Seoul National University, Suwon, 16229, Korea
| | - Ji-Ae Song
- Medicinal Bioconvergence Research Center, Seoul National University, Suwon, 16229, Korea
| | - Moo-Seung Lee
- Infectious Disease Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon, 34141, Korea
| | - Sunghoon Kim
- Medicinal Bioconvergence Research Center, Seoul National University, Suwon, 16229, Korea.
| | - Yong-Sung Kim
- Department of Molecular Science and Technology, Ajou University, Suwon, 16499, Korea.
| |
Collapse
|
10
|
Szabelska A, Tatara MR, Krupski W. Interrelationships between Bone Metabolism Markers and Deciduous Teeth and Mandible Properties in Polish Merino Sheep. J HARD TISSUE BIOL 2017. [DOI: 10.2485/jhtb.26.249] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Anna Szabelska
- Department of Prosthetic Dentistry, Medical University in Lublin
| | - Marcin R. Tatara
- Department of Animal Physiology, Faculty of Veterinary Medicine, University of Life Sciences in Lublin
- II Department of Radiology, Medical University in Lublin
| | - Witold Krupski
- II Department of Radiology, Medical University in Lublin
| |
Collapse
|
11
|
van de Lagemaat M, van der Veer E, van Weissenbruch MM, Lafeber HN, Rotteveel J. Procollagen type I N-terminal peptide in preterm infants is associated with growth during the first six months post-term. Clin Endocrinol (Oxf) 2014; 81:551-8. [PMID: 24655054 DOI: 10.1111/cen.12454] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Revised: 12/15/2013] [Accepted: 03/17/2014] [Indexed: 10/25/2022]
Abstract
OBJECTIVE To identify growth-related collagen and bone parameters in small-for-gestational-age (SGA) and appropriate-for-gestational-age (AGA) preterm infants during the first six months post-term. In SGA preterm infants, increased growth and decreased bone acquisition, which we demonstrated previously, may be reflected by these markers. DESIGN Observational study within a randomized controlled trial. PATIENTS Thirty-three SGA (weight, length or both at birth <-2 SDS) and 98 AGA preterm infants (gestational age [median (IQR)]: 31·1 (1·6) vs 30·3 (2·0) weeks; 72·7% vs 42·9% boys). MEASUREMENTS Weight (g), length (cm), procollagen type I N-terminal peptide (PINP; μg/l), urinary helical peptide (UHP; μg/mmol creatinine) and alkaline phosphatase (ALP; U/l) expressed as standard deviation scores (SDS) at term age, three and six months post-term. RESULTS Weight and length gain during the first six months post-term and PINP SDS at term age, three months and six months post-term were higher in SGA compared with AGA infants. UHP SDS and ALP SDS were similar in SGA and AGA infants. PINP SDS and UHP SDS at term age and PINP SDS at three months were associated with subsequent weight and length gain until six months post-term. CONCLUSIONS Increased growth in SGA compared with AGA preterm infants is reflected by increased collagen type I synthesis during the first six months post-term, suggesting that PINP and UHP correspond with growth in preterm infants. An explanation for decreased bone acquisition of SGA preterm infants may be that increased collagen type I synthesis is not directly followed by increased bone mineralization.
Collapse
|
12
|
Faje AT, Fazeli PK, Miller KK, Katzman DK, Ebrahimi S, Lee H, Mendes N, Snelgrove D, Meenaghan E, Misra M, Klibanski A. Fracture risk and areal bone mineral density in adolescent females with anorexia nervosa. Int J Eat Disord 2014; 47:458-66. [PMID: 24430890 PMCID: PMC4053520 DOI: 10.1002/eat.22248] [Citation(s) in RCA: 111] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/22/2013] [Revised: 11/20/2013] [Accepted: 12/22/2013] [Indexed: 11/10/2022]
Abstract
OBJECTIVE To (i) compare fracture prevalence in adolescent females with anorexia nervosa (AN) versus normal-weight controls and (ii) examine whether reductions in areal bone mineral density (aBMD) predict fracture risk in females with AN. METHOD Four-hundred eighteen females (310 with active AN and 108 normal-weight controls) 12- to 22-years-old were studied cross-sectionally. Lifetime fracture history was recorded by a physician during participant interviews. Body composition and aBMD measurements of the whole body, whole body less head, lumbar spine, and hip were assessed by dual-energy X-ray absorptiometry, and bone mineral apparent density (BMAD) was calculated for the lumbar spine. RESULTS Participants with AN and normal-weight controls did not differ for chronological age, sexual maturity, or height. The lifetime prevalence of prior fracture was 59.8% higher in those with AN as compared to controls (31.0% vs. 19.4%, p = 0.02), and the fracture incidence rate peaked in our cohort after the diagnosis of AN. Lower aBMD and lumbar BMAD were not associated with a higher prevalence of fracture in the AN or control group on univariate or multivariate analyses. Compared to controls, fracture prevalence was significantly higher in the subgroup of girls with AN who had normal aBMD or only modest reductions of aBMD (Z-scores > -1 or -1.5). DISCUSSION This is the first study to show that the risk of fracture during childhood and adolescence is significantly higher in patients with AN than in normal-weight controls. Fracture prevalence is increased in this cohort of participants with AN even without significant reductions in aBMD.
Collapse
Affiliation(s)
- Alexander T. Faje
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, USA
| | - Pouneh K. Fazeli
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, USA
| | - Karen K. Miller
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, USA
| | - Debra K. Katzman
- Division of Adolescent Medicine, Department of Pediatrics, Hospital
for Sick Children and University of Toronto, Toronto, Ontario, Canada
| | - Seda Ebrahimi
- Cambridge Eating Disorders Center, Cambridge, MA, USA
| | - Hang Lee
- Biostatistics Center, Massachusetts General Hospital, Boston, MA,
USA
| | - Nara Mendes
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, USA
| | - Deirdre Snelgrove
- Division of Adolescent Medicine, Department of Pediatrics, Hospital
for Sick Children and University of Toronto, Toronto, Ontario, Canada
| | - Erinne Meenaghan
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, USA
| | - Madhusmita Misra
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, USA,Pediatric Endocrine Unit, Massachusetts General Hospital for
Children and Harvard Medical School, Boston, MA, USA
| | - Anne Klibanski
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard
Medical School, Boston, MA, USA
| |
Collapse
|
13
|
Faje AT, Karim L, Taylor A, Lee H, Miller KK, Mendes N, Meenaghan E, Goldstein MA, Bouxsein ML, Misra M, Klibanski A. Adolescent girls with anorexia nervosa have impaired cortical and trabecular microarchitecture and lower estimated bone strength at the distal radius. J Clin Endocrinol Metab 2013; 98:1923-9. [PMID: 23509107 PMCID: PMC3644600 DOI: 10.1210/jc.2012-4153] [Citation(s) in RCA: 72] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
CONTEXT Adolescents with anorexia nervosa (AN) have low areal bone mineral density (aBMD) at both cortical and trabecular sites, and recent data show impaired trabecular microarchitecture independent of aBMD. However, data are lacking regarding both cortical microarchitecture and bone strength assessment by finite element analysis (FEA) in adolescents with AN. Because microarchitectural abnormalities and FEA may predict fracture risk independent of aBMD, these data are important to obtain. OBJECTIVE Our objective was to compare both cortical and trabecular bone microarchitecture and FEA estimates of bone strength in adolescent girls with AN vs normal-weight controls. DESIGN, SETTING, AND SUBJECTS We conducted a cross-sectional study at a clinical research center that included 44 adolescent girls (21 with AN and 23 normal-weight controls) 14 to 22 years old. MAIN OUTCOME MEASURES We evaluated 1) aBMD (dual-energy x-ray absorptiometry) at the distal radius, lumbar spine, and hip, 2) cortical and trabecular microarchitecture at the ultradistal radius (high-resolution peripheral quantitative computed tomography), and 3) FEA-derived estimates of failure load at the ultradistal radius. RESULTS aBMD was lower in girls with AN vs controls at the lumbar spine and hip but not at the distal radius. Girls with AN had lower total (P < .0001) and trabecular volumetric BMD (P = .02) and higher cortical porosity (P = .03) and trabecular separation (P = .04). Despite comparable total cross-sectional area, trabecular area was higher in girls with AN (P = .04), and cortical area and thickness were lower (P = .002 and .02, respectively). FEA-estimated failure load was lower in girls with AN (P = .004), even after controlling for distal radius aBMD. CONCLUSIONS Both cortical and trabecular microarchitecture are altered in adolescent girls with AN. FEA-estimated failure load is decreased, indicative of reduced bone strength. The finding of reduced cortical bone area in girls with AN is consistent with impaired cortical bone formation at the endosteum as a mechanism underlying these findings.
Collapse
Affiliation(s)
- Alexander T Faje
- Neuroendocrine Unit, Massachusetts General Hospital for Children, Boston, Massachusetts 02114, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Wyness SP, Roberts WL, Straseski JA. Pediatric reference intervals for four serum bone markers using two automated immunoassays. Clin Chim Acta 2013; 415:169-72. [DOI: 10.1016/j.cca.2012.10.036] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2012] [Revised: 10/16/2012] [Accepted: 10/17/2012] [Indexed: 10/27/2022]
|
15
|
Effect of growth hormone insulin-like growth factor 1 axis on bone turnover in Egyptian adolescent girls with anorexia nervosa. MIDDLE EAST CURRENT PSYCHIATRY 2013. [DOI: 10.1097/01.xme.0000422812.25195.23] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
16
|
Faje AT, Fazeli PK, Katzman DK, Miller KK, Breggia A, Rosen CJ, Mendes N, Klibanski A, Misra M. Sclerostin levels and bone turnover markers in adolescents with anorexia nervosa and healthy adolescent girls. Bone 2012; 51:474-9. [PMID: 22728230 PMCID: PMC3412913 DOI: 10.1016/j.bone.2012.06.006] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2012] [Revised: 05/12/2012] [Accepted: 06/06/2012] [Indexed: 11/15/2022]
Abstract
Sclerostin, product of the SOST gene, is an important determinant of bone formation and resorption. Adolescents with anorexia nervosa (AN) have low bone density and decreased levels of bone turnover markers. However, sclerostin has not been examined in AN as a potential mediator of impaired bone metabolism. Our study objectives were to (i) assess associations of sclerostin with surrogate bone turnover markers in girls with AN and controls and (ii) examine effects of transdermal estradiol on sclerostin in AN. 69 girls (44 with AN and 25 normal-weight controls) 13-18 years old were studied at baseline. 22 AN girls were randomized to transdermal estradiol (plus cyclic medroxyprogesterone) or placebo in a double-blind study for 12 months. Sclerostin correlated positively with P1NP and CTX in controls (r=0.67 and 0.53, p=0.0002 and 0.005, respectively) but not in AN despite comparable levels at baseline. Changes in sclerostin over twelve months did not differ in girls randomized to estradiol or placebo. The relationship between sclerostin and bone turnover markers is disrupted in adolescent girls with AN. Despite an increase in BMD with estradiol administration in AN, estrogen does not impact sclerostin levels in this group.
Collapse
Affiliation(s)
- Alexander T. Faje
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
| | - Pouneh K. Fazeli
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
| | - Debra K. Katzman
- Division of Adolescent Medicine, Hospital for Sick Children, Toronto, Ontario, Canada
| | - Karen K. Miller
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
| | - Anne Breggia
- Maine Medical Center Research Institute, Portland, ME 04074
| | | | - Nara Mendes
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
| | - Anne Klibanski
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
| | - Madhusmita Misra
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114
- Pediatric Endocrine Unit, Massachusetts General Hospital for Children and Harvard Medical School, Boston, MA 02114
| |
Collapse
|
17
|
Abstract
Osteogenesis imperfecta (OI) is a heritable form of bone fragility typically associated with a dominant COL1A1 or COL1A2 mutation. Variable phenotype for OI patients with identical collagen mutations is well established, but phenotype variability is described using the qualitative Sillence classification. Patterning a new OI mouse model on a specific collagen mutation therefore has been hindered by the absence of an appropriate kindred with extensive quantitative phenotype data. We benefited from the large sibships of the Old Order Amish (OOA) to define a wide range of OI phenotypes in 64 individuals with the identical COL1A2 mutation. Stratification of carrier spine (L1-4) areal bone mineral density (aBMD) Z-scores demonstrated that 73% had moderate to severe disease (less than -2), 23% had mild disease (-1 to -2), and 4% were in the unaffected range (greater than -1). A line of knock-in mice was patterned on the OOA mutation. Bone phenotype was evaluated in four F(1) lines of knock-in mice that each shared approximately 50% of their genetic background. Consistent with the human pedigree, these mice had reduced body mass, aBMD, and bone strength. Whole-bone fracture susceptibility was influenced by individual genomic factors that were reflected in size, shape, and possibly bone metabolic regulation. The results indicate that the G610C OI (Amish) knock-in mouse is a novel translational model to identify modifying genes that influence phenotype and for testing potential therapies for OI.
Collapse
|
18
|
Ezzat WM, . HMR, . AE, . MM, . MMA, . NAEG, . EAR. Bone Mineral Density and Bone Turnover Markers in Chronic Liver Disease. JOURNAL OF MEDICAL SCIENCES 2007. [DOI: 10.3923/jms.2007.748.754] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|
19
|
Yang L, Grey V. Pediatric reference intervals for bone markers. Clin Biochem 2006; 39:561-8. [PMID: 16423337 DOI: 10.1016/j.clinbiochem.2005.11.015] [Citation(s) in RCA: 78] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2005] [Revised: 11/15/2005] [Accepted: 11/29/2005] [Indexed: 01/29/2023]
Abstract
Bone markers are specific bone-derived molecules that reflect bone remodeling activity and can be classified into two categories: bone formation and bone resorption markers. Children have significantly elevated bone marker levels due to high skeletal growth velocity and rapid bone turnover during childhood growth. Many physiological and pathological processes may influence bone metabolism and bone marker concentrations during childhood growth. Measurements of bone markers may be useful in investigating skeletal diseases in children and monitoring the response to treatment. This review documents recent advances in analytical methods, preanalytical considerations related to each marker and particularly highlights the most valuable bone formation markers, bone alkaline phosphatase and osteocalcin, and bone resorption markers, pyridinium cross-links and cross-linked telopeptides. Age- and sex-specific pediatric reference intervals and their limitations in clinical application are also discussed.
Collapse
Affiliation(s)
- Liju Yang
- Department of Pathology and Molecular Medicine, Hamilton Regional Laboratory Medicine Program, McMaster University Medical Centre, McMaster University, Room 2N17, 1200 Main Street W, Hamilton, ON, Canada L8N 3Z5
| | | |
Collapse
|
20
|
Marini JC, Hopkins E, Glorieux FH, Chrousos GP, Reynolds JC, Gundberg CM, Reing CM. Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: high predictive value of the carboxyterminal propeptide of type I procollagen. J Bone Miner Res 2003; 18:237-43. [PMID: 12568401 DOI: 10.1359/jbmr.2003.18.2.237] [Citation(s) in RCA: 58] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Extreme short stature is a cardinal feature of severe osteogenesis imperfecta (OI), types III and IV. We conducted a treatment trial of growth hormone in children with OI and followed linear growth velocity, bone metabolism markers, histomorphometrics, and vertebral bone density. Twenty-six children with types III and IV OI, ages 4.5-12 years, were treated with recombinant growth hormone (rGH), 0.1-0.2 IU/kg per day for 6 days/week, for at least 1 year. Length, insulin-like growth factor (IGF-I), insulin-like growth factor binding protein (IGFBP-3), bone metabolic markers, and vertebral bone density by DXA were evaluated at 6-month intervals. An iliac crest biopsy was obtained at baseline and 12 months. Approximately one-half of the treated OI children sustained a 50% or more increase in linear growth over their baseline growth rate. Most responders (10 of 14) had moderate type IV OI. All participants had positive IGF-I, IGFBP-3, osteocalcin, and bone-specific alkaline phosphatase responses. Only the linear growth responders had a significant increase in vertebral DXA z-score and a significant decrease in long bone fractures. After 1 year of treatment, responders' iliac crest biopsy showed significant increases in cancellous bone volume, trabecular number, and bone formation rate. Responders were distinguished from nonresponders by higher baseline carboxyterminal propeptide (PICP) values (p < 0.05), suggesting they have an intrinsically higher capacity for collagen production. The results show that growth hormone can cause a sustained increase in the linear growth rate of children with OI, despite the abnormal collagen in their bone matrix. In the first year of treatment, growth responders achieve increased bone formation rate and density, and decreased fracture rates. The baseline plasma concentration of PICP was an excellent predictor of positive response.
Collapse
Affiliation(s)
- Joan C Marini
- Section on Connective Tissue Disorders, HDB, NICHD, National Institutes of Health, Bethesda, Maryland 20892, USA.
| | | | | | | | | | | | | |
Collapse
|
21
|
Schoenau E, Rauch F. Biochemical Measurements of Bone Metabolism in Childhood and Adolescence/Biochemische Messungen des Knochenstoffwechsels in Kindheit und Adoleszenz. ACTA ACUST UNITED AC 2003. [DOI: 10.1515/labmed.2003.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
22
|
Seibold-Weiger K, Wollmann HA, Ranke MB, Speer CP. Plasma concentrations of the carboxyterminal propeptide of type I procollagen (PICP) in preterm neonates from birth to term. Pediatr Res 2000; 48:104-8. [PMID: 10879807 DOI: 10.1203/00006450-200007000-00018] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Carboxyterminal propeptide of type I procollagen (PICP), a marker of bone formation, has not yet been studied in preterm infants. In this study, PICP concentrations were measured longitudinally for 12 wk after birth using the ELISA technique in 43 preterm infants with a gestational age (GA) ranging from 24-29 wk and in 35 preterm infants with a GA ranging from 30-34 wk. PICP values in these preterm infants were higher than in children and adults. In cord plasma of preterm infants there was a significant gender difference, with higher PICP concentrations in male infants. A characteristic longitudinal pattern with an initial decrease during the first 3 postnatal days followed by a rapid increase from d 7 to d 28 was seen in both groups. Regarding the individual gestational ages, all preterm infants attained maximum PICP concentrations around 36 wk postmenstrual age. Multiple regression analysis revealed cord plasma PICP concentrations were significantly associated with GA, birth weight, sex, and IGF-I. A significant correlation between PICP concentrations and GA was seen at wk 1-4 and between PICP concentrations and protein intake at wk 1. Body weight and energy intake were shown to exert a significant effect on the PICP concentrations at 2 wk. The collected data in preterm infants may serve further studies evaluating PICP as a marker for bone formation and growth in very low birth weight premature infants.
Collapse
Affiliation(s)
- K Seibold-Weiger
- University of Tübingen, Children's Hospital, Department of Neonatology, Germany
| | | | | | | |
Collapse
|
23
|
Hytinantti T, Rutanen EM, Turpeinen M, Sorva R, Andersson S. Markers of collagen metabolism and insulin-like growth factor binding protein-1 in term infants. Arch Dis Child Fetal Neonatal Ed 2000; 83:F17-20. [PMID: 10873165 PMCID: PMC1721109 DOI: 10.1136/fn.83.1.f17] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
AIM To study the relation between fetal growth and markers of collagen metabolism and insulin-like growth factor binding protein-1 (IGFBP-1) in term infants. METHODS Cord vein plasma was obtained from 67 term infants of gestational age 37.1-41.7 weeks (39 appropriate for gestational age (AGA), 11 large for gestational age (LGA; relative birth weight >/= 2.0 SD), and 17 small for gestational age (SGA; relative birth weight </= -2.0 SD)) for analysis of markers of metabolism of collagen type I (PICP and ICTP) and III (PIIINP) and of IGFBP-1. RESULTS Negative correlations existed between gestational age and PICP (r = -0.294, p = 0.0158), ICTP (r = -0.338, p = 0.0052), and PIIINP (r = -0.432, p = 0.0003). These correlations were also found in SGA infants (all p < 0.05). IGFBP-1 showed negative correlations with birth weight and relative birth weight (r = -0.644, p = 0.0001, and r = -0.693, p = 0.0001 respectively) but not with gestational age (p>0.05). CONCLUSIONS In the term fetus, collagen metabolism is primarily dependent on maturity and not on intrauterine growth status, whereas IGFBP-1 reflects intrauterine growth independently of maturity.
Collapse
Affiliation(s)
- T Hytinantti
- Helsinki City Maternity Hospital, Helsinki, Finland
| | | | | | | | | |
Collapse
|
24
|
Rauch F, Travers R, Norman ME, Taylor A, Parfitt AM, Glorieux FH. Deficient bone formation in idiopathic juvenile osteoporosis: a histomorphometric study of cancellous iliac bone. J Bone Miner Res 2000; 15:957-63. [PMID: 10804027 DOI: 10.1359/jbmr.2000.15.5.957] [Citation(s) in RCA: 65] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
Idiopathic juvenile osteoporosis (IJO), a rare cause of osteoporosis in children, is characterized by the occurrence of vertebral and metaphyseal fractures. Little is known about the histopathogenesis of IJO. We analyzed by quantitative histomorphometry iliac crest biopsies from 9 IJO patients (age, 10.0-12.3 years; 7 girls) after tetracycline labeling. Results were compared with identically processed samples from 12 age-matched children without metabolic bone disease and 11 patients with osteogenesis imperfecta type I. Compared with healthy controls, cancellous bone volume (BV) was markedly decreased in IJO patients (mean [SD]: 10.0% [3.1%] vs. 24.4% [3.8%]), because of a 34% reduction in trabecular thickness (Tb.Th) and a 37% lower trabecular number (Tb.N; p < 0.0001 each; unpaired t-test). Bone formation rate (BFR) per bone surface was decreased to 38% of the level in controls (p = 0.0006). This was partly caused by decreased recruitment of remodeling units, as shown by a trend toward lower activation frequency (54% of the control value; p = 0.08). Importantly, osteoblast team performance also was impaired, as evidenced by a decreased wall thickness (W.Th; 70% of the control value; p < 0.0001). Reconstruction of the formative sites revealed that osteoblast team performance was abnormally low even before mineralization started at a given site. No evidence was found for increased bone resorption. Compared with children with osteogenesis imperfecta (OI), IJO patients had a similarly decreased cancellous BV but a much lower bone turnover. These results suggest a pathogenetic model for IJO, in which impaired osteoblast team performance decreases the ability of cancellous bone to adapt to the increasing mechanical needs during growth. This will finally result in load failure at sites where cancellous bone is essential for stability.
Collapse
Affiliation(s)
- F Rauch
- Genetics Unit, Shriners Hospital, McGill University, Montréal, Québec, Canada
| | | | | | | | | | | |
Collapse
|
25
|
Bollen AM. A prospective longitudinal study of urinary excretion of a bone resorption marker in adolescents. Ann Hum Biol 2000; 27:199-211. [PMID: 10768424 DOI: 10.1080/030144600282307] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
Abstract
In growing subjects, the rates of bone resorption and bone deposition are substantially larger than in non-growing individuals. The purpose of this study was to measure the urinary excretion of a specific bone resorption marker in function of adolescent growth stages in a prospective longitudinal study. A cohort of 60 adolescents (28 male and 32 female) was followed for 3.4 years (range 1.7-4.6 years). Monthly measurements of height, weight and urinary excretion of a bone resorption marker, collagen type I N-telopeptides (NTx), were made. Changes in standing height were used to classify the adolescents into one or more of six adolescent growth stages: pre-pubertal growth (continuous moderate growth rate), ascending growth spurt (increasing growth rate), peak growth spurt (growth rate higher than 7 cm/year for at least 6 months), descending growth spurt (continuous decrease in growth rate), end of growth (growth rate between 0 and 2 cm/year), and no growth. An increase in NTx excretion from the pre-pubertal to peak growth spurt of about 33% was found (44% and 27% for females and males respectively). The decreasing growth rate after the pubertal growth spurt coincided with a clear decrease in NTx excretion. These differences were statistically significant, except between the prepubertal and ascending growth stage. Individual mean NTx excretion during each growth stage was correlated with the individual's growth rate during that time (r = 0.81). There was large inter-and intra individual variability. In non-growing adolescents (growth rate 0 cm/y) NTx excretion levels were 4-7 times greater than in adults. In all females, menarche was followed by a decrease in NTx excretion. In conclusion, the excretion of a specific bone resorption marker, NTx, was correlated with the changes in growth rate during adolescence, both for males and females. There were large inter and intra-individual differences in NTx excretion during the different growth stages. In adolescents who reached their adult height at the end of the pubertal growth spurt. bone resorption decreased dramatically but remained 4-7 fold higher than in adults.
Collapse
Affiliation(s)
- A M Bollen
- Department of Orthodontics, University of Washington, Seattle 98195, USA.
| |
Collapse
|
26
|
Soyka LA, Grinspoon S, Levitsky LL, Herzog DB, Klibanski A. The effects of anorexia nervosa on bone metabolism in female adolescents. J Clin Endocrinol Metab 1999; 84:4489-96. [PMID: 10599707 DOI: 10.1210/jcem.84.12.6207] [Citation(s) in RCA: 83] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Osteopenia is a frequent, often persistent, complication of anorexia nervosa (AN) in adolescent girls and occurs during a critical time in bone development. Little is known about bone metabolism in this patient population. Therefore, we measured bone density (BMD) and body composition by dual energy x-ray absorptiometry, nutritional status, bone turnover, calcium, and hormonal status in 19 adolescent girls with AN (mean +/- SEM, 16.0+/-0.4 yr) and 19 bone age-matched controls. The mean duration of AN was 19+/-5 months. Spinal (L1-L4) osteopenia was common in AN. Lumbar anterioposterior BMD was more than 1 SD below the mean in 42% of patients, and lateral spine BMD was more than 1 SD below in 63% of patients compared with controls. Lean body mass significantly predicted lumbar bone mineral content (r = 0.75; P < 0.0001) in controls only. In AN, duration of illness was the most significant predictor of spinal BMD (lumbar: r = -0.44; P = 0.06; lateral: r = -0.59; P = 0.008). AN adolescents with mature BA (15 yr and greater) were hypogonadal [estradiol, 16.2+/-1.9 vs. 23.3+/-1.6 pg/mL (P = 0.01); free testosterone, 0.70+/-0.17 vs. 1.36+/-0.14 pg/mL (P = 0.01)] although dehydroepiandrosterone sulfate and urinary free cortisol levels did not differ. Leptin levels were reduced in AN (2.9+/-2.1 vs. 16.5+/-1.8 ng/mL; P < 0.0001). Insulin-like growth factor I (IGF-I) was reduced in AN to 50% of control levels (219+/-41 vs. 511+/-35 ng/mL; P < 0.0001) and correlated with all measures of nutritional status, particularly leptin (r = 0.80; P < 0.0001). Surrogate markers of bone formation, serum osteocalcin (OC) and bone-specific alkaline phosphatase (BSAP), were significantly (P = 0.02) reduced in AN vs. controls (OC, 39.1+/-6.4 vs. 59.2+/-5.2 ng/mL; BSAP, 27.9+/-4.0 vs. 40.6+/-3.4 U/L). The majority of the variation in bone formation in AN was due to IGF-I levels (OC: r2 = 0.72; P = 0.002; BSAP: r2 = 0.53; P = 0.01) in stepwise regression analyses. Bone resorption was comparable in patients and controls. These data demonstrate that bone formation is reduced and uncoupled to bone resorption in mature adolescents with AN in association with low bone density. Lean body mass was a significant predictor of BMD in controls, but not AN patients. The major correlate of bone formation in AN was the nutritionally dependent bone trophic factor, IGF-I. Reduced IGF-I during the critical period of bone mineral accumulation may be an important factor in the development of osteopenia in adolescents with AN.
Collapse
Affiliation(s)
- L A Soyka
- Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA
| | | | | | | | | |
Collapse
|
27
|
Abstract
As the mean age of our population increases, increasing attention has been paid to the diseases associated with aging, including diseases of the skeleton such as osteoporosis. Effective means of treating and possibly preventing such skeletal disorders are emerging, making their early recognition an important goal for the primary care physician. Although bone density measurements and skeletal imaging studies remain of primary diagnostic importance in this regard, a large number of assays for biochemical markers of bone formation and resorption are being developed that promise to complement the densitometry measurements and imaging studies, providing an assessment of the rates of bone turnover and an earlier evaluation of the effects of therapy. In this review, emphasizing the recent literature, the major biochemical markers currently in use or under active investigation are described, and their application in a number of diseases of the skeleton including osteoporosis is evaluated.
Collapse
Affiliation(s)
- D D Bikle
- University of California and Veterans Administration Medical Center, San Francisco 94121, USA
| |
Collapse
|
28
|
Sorva R, Anttila R, Siimes MA, Sorva A, Tähtelä R, Turpeinen M. Serum markers of collagen metabolism and serum osteocalcin in relation to pubertal development in 57 boys at 14 years of age. Pediatr Res 1997; 42:528-32. [PMID: 9380448 DOI: 10.1203/00006450-199710000-00018] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We investigated whether levels of serum collagen markers and serum osteocalcin are related to pubertal growth and development in a cross-sectional study of 57 healthy boys at 14 y of age. The level of the soft tissue marker, serum amino-terminal propeptide of type III procollagen (PIIINP) was higher in boys at Tanner stages G3 versus G2 (p < 0.01). The levels of the markers of bone collagen matrix differed only at a more advanced pubertal stage: the formation markers, carboxy-terminal and amino-terminal propeptides of type I procollagen, and the degradation marker, carboxy-terminal telopeptide of type I collagen were higher only at stage G4 versus G3 (p < 0.01). The marker of bone mineralization, serum osteocalcin was also higher only at stage G4 versus G3 (p < 0.01). Stage G4 was associated with the pubertal growth spurt. The results demonstrate that pubertal development should be taken into account when serum levels of collagen markers and osteocalcin are evaluated, and suggest that an increase in serum PIINP in boys at G3 might predict a normal pubertal growth spurt, but the finding remains to be confirmed in longitudinal studies.
Collapse
Affiliation(s)
- R Sorva
- Department of Allergic Diseases, University of Helsinki, Finland
| | | | | | | | | | | |
Collapse
|
29
|
Zanze M, Souberbielle JC, Kindermans C, Rossignol C, Garabedian M. Procollagen propeptide and pyridinium cross-links as markers of type I collagen turnover: sex- and age-related changes in healthy children. J Clin Endocrinol Metab 1997; 82:2971-7. [PMID: 9284729 DOI: 10.1210/jcem.82.9.4207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
The correlations among age, gender, body size parameters, and type I collagen metabolism were evaluated in 183 healthy infants, aged 8.5-27.5 months. Collagen formation was assessed by measuring serum type I collagen carboxy-terminal propeptide, and degradation was determined by urinary pyridinoline and deoxypyridinoline (measured by high performance liquid chromatography) and cross-linked N- and C-terminal telopeptides of type I collagen (measured by NTx and CrossLaps assays). A new RIA specific for deoxypyridinoline was also evaluated. The results provide reference values at 10 months and 2 yr of age, including cross-linked C-terminal telopeptides (1492 +/- 685 and 1510 +/- 446 in boys; 1705 +/- 612 and 1849 +/- 611 micrograms/mmol creatinine in girls; mean +/- 1 SD). There was a good correlation between the high performance liquid chromatography and RIA data for deoxypyridinoline, showing that the RIA method is suitable for use in healthy children. Some correlations were found among peptide-bound cross-links, serum type I collagen carboxy-terminal propeptide, and the anthropometric parameters, suggesting that these peptides reflect bone resorption and also overall body type I collagen. Finally, there were age- and sex-related differences in the urinary excretion of the collagen degradation markers, suggesting that, unlike boys, girls maintain a high degree of collagen degradation up to the age of 24 months despite a decrease in their rate of collagen formation.
Collapse
Affiliation(s)
- M Zanze
- CNRS URA 583, Université Paris V, Hôpital St. Vincent de Paul, France
| | | | | | | | | |
Collapse
|
30
|
Crofton PM, Wade JC, Taylor MRH, Holland CV. Serum concentrations of carboxyl-terminal propeptide of type I procollagen, amino-terminal propeptide of type III procollagen, cross-linked carboxyl-terminal telopeptide of type I collagen, and their interrelationships in schoolchildren. Clin Chem 1997. [DOI: 10.1093/clinchem/43.9.1577] [Citation(s) in RCA: 46] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Abstract
We report pediatric age- and sex-specific 95% reference intervals for procollagen type I C-terminal propeptide (PICP), the cross-linked C-terminal telopeptide of type I collagen (ICTP), and procollagen type III N-terminal propeptide (P3NP), measured in plasma from 302 schoolchildren (156 boys, 146 girls) ages 4–19 years. All three markers displayed a significant variation with age (ANOVA P ≤0.0015). PICP showed no detectable increase during adolescence for either sex, but decreased towards adult concentrations after the age of puberty, with an earlier decrease for girls than for boys (P <0.01). ICTP and P3NP both increased in pubertal-aged children (P <0.05), with an earlier increase in girls than in boys (P <0.05), before decreasing towards adult concentrations (P <0.01). All three collagen markers were highly correlated with one another (P <0.001). The patterns observed mirrored the childhood growth curve and reflected the high turnover of bone and soft tissue during childhood growth.
Collapse
Affiliation(s)
- Patricia M Crofton
- Department of Paediatric Biochemistry, Royal Hospital for Sick Children, Sciennes Rd., and Department of Child Life and Health, University of Edinburgh, 20 Sylvan Place, Edinburgh EH9 1LF, Scotland, UK
| | - Jean C Wade
- Department of Paediatric Biochemistry, Royal Hospital for Sick Children, Sciennes Rd., and Department of Child Life and Health, University of Edinburgh, 20 Sylvan Place, Edinburgh EH9 1LF, Scotland, UK
| | - Mervyn R H Taylor
- Department of Paediatrics, Trinity College, Dublin and the National Children’s Hospital, Harcourt St., Dublin 2, Ireland
| | | |
Collapse
|
31
|
Falorni A, Bini V, Cabiati G, Papi F, Arzano S, Celi F, Sanasi M. Serum levels of type I procollagen C-terminal propeptide, insulin-like growth factor-I (IGF-I), and IGF binding protein-3 in obese children and adolescents: relationship to gender, pubertal development, growth, insulin, and nutritional status. Metabolism 1997; 46:862-71. [PMID: 9258266 DOI: 10.1016/s0026-0495(97)90071-8] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
We measured fasting serum levels of type I procollagen C-terminal propeptide (PICP), insulin-like growth factor-I (IGF-I), and IGF binding protein-3 (IGFBP-3) in obese children and adolescents (obese subjects [OS]) to evaluate their relationship to growth, gender, pubertal stage, and weight excess (WE). The influence of insulin, growth hormone (GH), and weight loss was also studied. The study population consisted of 244 OS and 236 normal-weight subjects (NWS) matched for age, gender, and pubertal stage. At stage I, OS had a higher standard deviation score (SDS) for height than NWS of both genders. During the prepubertal phase, growth velocity (GV) was greater in OS than in NWS of both genders, but it was lower in female OS at stage II and male OS at stage III. PICP increased in puberty, with a more rapid decrease later in female OS and NWS; prepubertal values were higher in OS but were reduced at pubertal stage IV to V in comparison to NWS. Stepwise multiple regression analysis demonstrated that GV was the only anthropological variable correlating with PICP. IGF-I serum values increased significantly in puberty and were higher in OS than in NWS at stage I for both genders. IGFBP-3 values of OS exceeded those of NWS at stages I to III in males and I to II in females. No difference was observed for males versus females in each group, nor was any difference observed for the IGF-I/IGFBP-3 molar ratio between the two groups. Using stepwise analysis, a positive correlation between IGF-1 and IGFBP-3 was observed in prepubertal but not in pubertal NWS. Fasting insulin values correlated with IGFBP-3 in OS, accounting for 24.8% of the variation in prepubertal subjects and 17.1% in pubertal subjects. No such correlation was observed in NWS. In prepubertal NWS, PICP and SDS of body mass index (BMI) correlated with IGF-I, accounting for 12.9% of the variation, and SDS of BMI correlated with IGFBP-3, explaining 27.8% of the variation. In prepubertal OS, no such correlations could be observed, but PICP and SDS of BMI accounted for 14.3% of the variation in the IGF-I/IGFBP-3 molar ratio. A significant reduction of IGFBP-3 and an increase of the IGF-I/IGFBP-3 molar ratio were detected after weight loss in 40 OS. In conclusion, we demonstrated that IGF-I and IGFBP-3 are influenced by age, gender, sexual development, and nutritional status. Also, an influence of insulin on IGFBP-3 serum levels was observed in OS. The relations of IGF-I to PICP in NWS and of the IGF-I/IGFBP-3 molar ratio to PICP in OS support the concept of IGF-I influence on skeletal growth. The increased IGFBP-3 serum values in OS suggest a possible role in controlling the growth stimulus induced by nutritional status.
Collapse
Affiliation(s)
- A Falorni
- Pediatric Clinic, University of Perugia, Terni, Italy
| | | | | | | | | | | | | |
Collapse
|
32
|
von Moers A, Danne T, Möller P, Scheffner D. Serum levels of carboxyterminal propeptide of type I procollagen, aminoterminal propeptide of type III procollagen and laminin P1 in Duchenne muscular dystrophy. Acta Paediatr 1997; 86:377-80. [PMID: 9174223 DOI: 10.1111/j.1651-2227.1997.tb09026.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
The striking proliferation of connective tissue in Duchenne muscular dystrophy is attributed, besides other components of the extracellular matrix, to an increase of endomysial and perimysial type III and type I collagen. We investigated if muscle fibrosis correlates to an increased serum concentration of procollagen I or III. Therefore, we measured the serum levels of carboxyterminal propeptide of type I procollagen, aminoterminal propeptide of type III procollagen and laminin P1 in 20 boys with progressive muscular dystrophy (16 definite Duchenne muscular dystrophy, 2 suspected of Duchenne muscular dystrophy, 2 Becker muscular dystrophy). In contrast to collagen I and III the expression of laminin in the basement membrane is known to be normal in Duchenne muscular dystrophy. There was no significant alteration of serum concentration of procollagen III N-peptide, procollagen I C-peptide and laminin P1 in boys with Duchenne muscular dystrophy. Measuring these parameters is not useful for investigating the extent of muscle fibrosis or for monitoring the effect of therapeutic trials such as steroid treatment.
Collapse
Affiliation(s)
- A von Moers
- Department of Neuropediatrics, Virchow-Klinikum, Humboldt University, Berlin, Germany
| | | | | | | |
Collapse
|
33
|
Baroncelli GI, De Luca F, Magazzú G, Arrigo T, Sferlazzas C, Catena C, Bertelloni S, Saggese G. Bone demineralization in cystic fibrosis: evidence of imbalance between bone formation and degradation. Pediatr Res 1997; 41:397-403. [PMID: 9078542 DOI: 10.1203/00006450-199703000-00016] [Citation(s) in RCA: 73] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
Bone turnover, collagen metabolism, and bone mineral status were investigated in 59 patients with cystic fibrosis and in 72 sex and age-matched control subjects. In all patients and control subjects serum concentrations of osteocalcin (OC), carboxy-terminal propeptide of type I procollagen (PICP), amino-terminal propeptide of type III procollagen (PIIINP), and cross-linked carboxy-terminal telopeptide of type I collagen (ICTP), and urinary values of cross-linked N-telopeptides of type I collagen (NTX), as well as total body bone mineral content (TBBM) were measured. Higher ICTP (microgram/L) and NTX (bone collagen equivalent/urinary creatinine (nmol/mmol) values were found in pre-pubertal, pubertal, and young adult patients than in control subjects (ICTP: 15.4 +/- 2.1 and 13.2 +/- 1.8, p < 0.001; 23.3 +/- 5.3 and 20.1 +/- 4.1, p < 0.02; 4.8 +/- 1.1 and 4.0 +/- 1.0, p < 0.05. respectively; NTX: 1047.5 +/- 528.6 and 227.8 +/- 71.8, p < 0.01; 997.8 +/- 391.7 and 376.3 +/- 91.0, p < 0.01; 993.2 +/- 398.0 and 73.9 +/- 28.5, p < 0.01, respectively). Lower OC and PICP levels (microgram/L) were showed in pubertal patients in comparison with control subjects (OC: 20.2 +/- 12.3 and 39.0 +/- 15.1, p < 0.01; PICP: 305.8 +/- 130.4 and 436.2 +/- 110.1, p < 0.02, respectively). Lower OC and higher PIIINP levels (microgram/L) were found in young adult patients than in control subjects (OC: 4.4 +/- 3.0 and 7.0 +/- 3.1, p < 0.05; PIIINP: 4.8 +/- 1.1 and 3.1 +/- 1.0, p < 0.001, respectively). TBBM (z score) was reduced in prepubertal, pubertal, and young adult patients (-0.8 +/- 0.4, -1.0 +/- 0.4, -1.1 +/- 0.5, respectively). Patients with cystic fibrosis have bone demineralization and imbalance between bone formation and degradation.
Collapse
|
34
|
Rotteveel J, Schoute E, Delemarre-van de Waal HA. Serum procollagen I carboxyterminal propeptide (PICP) levels through puberty: relation to height velocity and serum hormone levels. Acta Paediatr 1997; 86:143-7. [PMID: 9055882 DOI: 10.1111/j.1651-2227.1997.tb08855.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
The synthesis of type I collagen, the major component of the organic bone matrix, is reflected by procollagen I carboxyterminal propeptide (PICP) levels. Conflicting reports have been made about the relationship between PICP levels and puberty. We have studied PICP levels in serum in relation to pubertal stage, height velocity, oestradiol, testosterone, androstenedione, dehydroepiandrosterone sulphate, insulin-like growth factor I and growth hormone levels in 32 healthy boys aged 7.2-15.8 years and 32 healthy girls aged 7.2-14.8 years. The PICP levels in girls tended to be higher during midpuberty: in boys the levels were higher at the end of puberty. The PICP levels correlated strongly with height velocity in boys and girls. In conclusion, PICP correlates especially with height velocity. The variation of PICP between subjects during puberty is considerable. The PICP levels may predict growth at a certain moment, especially in cases where only one height measurement is available.
Collapse
Affiliation(s)
- J Rotteveel
- Department of Paediatrics, University Hospital Vrije Universiteit, Amsterdam, The Netherlands
| | | | | |
Collapse
|
35
|
Vihervuori E, Turpeinen M, Siimes MA, Koistinen H, Sorva R. Collagen formation and degradation increase during growth hormone therapy in children. Bone 1997; 20:133-8. [PMID: 9028537 DOI: 10.1016/s8756-3282(96)00332-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
A comprehensive set of serum markers of collagen turnover and growth was investigated in a longitudinal study of short children during growth induced by growth hormone (hGH) treatment. The study comprised 18 prepubertal children with short stature who had no other current illness or continuous medication. The growth rates and endogenous GH secretions covered a continuum from subnormal to normal. Before treatment, the concentrations of carboxyterminal propeptide of type I procollagen (PICP), reflecting type I collagen formation, of carboxyterminal telopeptide of type I collagen (ICTP), a degradation product of type I collagen, of amino-terminal propeptide of type III procollagen (PIIINP), a marker for type III collagen formation, of alkaline phosphatase (AP), and of insulin-like growth factor binding protein-3 (IGFBP-3) were within the lower limits of normal. The median IGF-I concentration was lower than the reference. One week after the start of treatment, the serum concentrations of ICTP, PIIINP, and osteocalcin (OC), and the increments in ICTP, PIIINP, and IGF binding protein-3 (IGFBP-3) correlated with the subsequent height velocity. During the 12-month treatment, all markers were higher than those of age-matched references, but only the three collagen markers paralleled the changes in height velocity. In molar concentrations, ICTP increased less than PICP. Throughout the study period, the serum level of ICTP correlated with that of PIIINP, but not with that of PICP. The findings suggest that during hGH treatment, linear body growth is closely associated with collagen formation and degradation.
Collapse
Affiliation(s)
- E Vihervuori
- Children's Hospital, University of Helsinki, Finland
| | | | | | | | | |
Collapse
|
36
|
Pratico G, Caltabiano L, Bottaro G, Palano GM, Rotolo N, Spina M. Serum levels of osteocalcin and type I procollagen in children with celiac disease. J Pediatr Gastroenterol Nutr 1997; 24:170-3. [PMID: 9106103 DOI: 10.1097/00005176-199702000-00010] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
BACKGROUND Bone metabolism may be disturbed in children with celiac disease. METHODS Two markers of bone turnover were used: the level of osteocalcin (BGP) and the level of carboxylterminal peptide of type I procollagen (PICP). BGP and PICP were measured by radioimmunoassays in 18 untreated children with celiac disease (mean age: 22.9 +/- 15.6 months) and in 15 control subjects (mean age 28.5 +/- 21 months). All the patients were rechecked after 1 month and again after 3 months from beginning of a gluten-free diet (GFD). RESULTS Compared with controls at diagnosis our patients had significantly lower serum levels of BGP and PICP (p = 0.003 and p = 0.018 by Student's t test, respectively). These levels increased markedly during the 1st 3 months of GFD. CONCLUSIONS The alteration in calcium phosphate homeostasis caused by celiac disease directly affects the synthesis of both components of the connective matrix of bone. Measurements of BGP and PICP provide a reliable and rapidly obtainable index of normalization of the processes of bone growth which can be achieved with a GFD.
Collapse
Affiliation(s)
- G Pratico
- First Department of Pediatrics, University of Catania, Sicily, Italy
| | | | | | | | | | | |
Collapse
|
37
|
Saggese G, Baroncelli GI, Bertelloni S, Perri G. Long-term growth hormone treatment in children with renal hypophosphatemic rickets: effects on growth, mineral metabolism, and bone density. J Pediatr 1995; 127:395-402. [PMID: 7658269 DOI: 10.1016/s0022-3476(95)70070-6] [Citation(s) in RCA: 55] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
OBJECTIVE To evaluate the effects of treatment with recombinant human growth hormone (rhGH) on growth, mineral metabolism, and bone density in children with renal hypophosphatemic rickets (RHR). DESIGN Long-term rhGH treatment combined with conventional therapy with 1,25-dihydroxyvitamin D3 plus inorganic phosphate salts. SETTING Endocrine unit, department of pediatrics, university hospital. SUBJECTS Twelve patients (5 boys; age range 4.6 to 12.5 years, median 7.0 years) were subdivided into two groups of six patients on the basis of the median of height z score (-2.41) and the median bone age/statural age (BA/SA) ratio (1.23). Group A included patients with a severe degree of short stature (height z score -3.4 +/- 0.5) (mean +/- SD) and altered BA/SA ratio (1.26 +/- 0.08); group B included patients with a lesser degree of short stature (height z score -2.1 +/- 0.6, p < 0.001 vs group A) and more normal BA/SA ratio (1.04 +/- 0.15, p < 0.01 vs group A). INTERVENTION Group A received rhGH treatment (0.6 IU/kg per week subcutaneously) combined with conventional therapy; group B received conventional therapy alone. MEASUREMENTS Height, growth velocity, predicted adult height, serum values of calcium, phosphate, bone alkaline phosphatase isoenzyme, osteocalcin, propeptides of type I and type III procollagen, intact parathyroid hormone, 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D, and urinary calcium/urinary creatinine ratio and tubular maximum for phosphate reabsorption normalized to the glomerular filtration rate (TmP/GFR), as well as radial bone density, were measured at baseline and for 3 years. RESULTS Height z score, growth velocity z score, predicted adult height, serum values of phosphate, bone alkaline phosphatase isoenzyme, osteocalcin, propeptides of type I and type III procollagen, intact parathyroid hormone 1,25-dihydroxyvitamin D, and TmP/GFR, as well as radial bone density, improved significantly only in group A. Serum calcium and 25-hydroxyvitamin D, and urinary calcium/urinary creatinine ratio did not change in either group. CONCLUSIONS Long-term rhGH administration may benefit growth, phosphate retention, and bone density in patients with RHR, without evidence of side effects.
Collapse
Affiliation(s)
- G Saggese
- Department of Pediatrics, University of Pisa, Italy
| | | | | | | |
Collapse
|
38
|
Grinspoon SK, Baum HB, Peterson S, Klibanski A. Effects of rhIGF-I administration on bone turnover during short-term fasting. J Clin Invest 1995; 96:900-6. [PMID: 7543494 PMCID: PMC185277 DOI: 10.1172/jci118137] [Citation(s) in RCA: 80] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023] Open
Abstract
Insulin-like growth factor-I (IGF-I) is a nutritionally dependent bone trophic hormone which stimulates osteoblast function and collagen synthesis in vivo and in vitro. We hypothesized that in the fasting state, IGF-I levels would decline significantly and would establish a model in which we could investigate the effects of IGF-I administration on bone turnover. We therefore studied 14 normal women ages 19-33 (mean, 24 +/- 4 [SD] years) during a complete 10-d fast. After 4 d of fasting, subjects were randomized to receive rhIGF-I or placebo subcutaneously twice a day for 6 d. Bone turnover was assessed using specific markers of formation (osteocalcin and type I procollagen carboxyl-terminal propeptide [PICP]) and resorption (pyridinoline, deoxypyridinoline, type I collagen crosslinked N-telopeptide [N-telopeptide] and hydroxyproline). Serum levels of PICP and osteocalcin decreased from 143 +/- 52 to 60 +/- 28 ng/ml (P = 0.001) and from 7.6 +/- 5.4 to 4.2 +/- 3.1 ng/ml (P = 0.001) respectively with 4 d of fasting. Urinary excretion of pyridinoline and deoxypyridinoline decreased from 96 +/- 63 to 47 +/- 38 nmol/mmol creatinine (P < 0.05) and from 28 +/- 17 to 14 +/- 11 nmol/mmol creatinine (P < 0.05) respectively. Mean IGF-I levels decreased from 310 +/- 81 to 186 +/- 78 ng/ml (P = 0.001). In the second part of the experimental protocol, serum osteocalcin and PICP levels increased 5- and 3-fold, respectively with rhIGF-I administration and were significantly elevated compared with the placebo group at the end of treatment (20.9 +/- 17.3 vs. 5.9 +/- 6.4 ng/ml for osteocalcin [P < 0.05] and 188 +/- 45 vs. 110 +/- 37 ng/ml for PICP [P < 0.05]). In contrast, all four markers of bone resorption, including urinary pyridinoline, deoxypyridinoline, N-telopeptide and hydroxyproline were unchanged with rhIGF-I administration. This report is the first to demonstrate that bone turnover falls rapidly with acute caloric deprivation in normal women. RhIGF-I administration uncouples bone formation in this setting by significantly increasing bone formation, but not resorption. These data suggest a novel use of rhIGF-I to selectively stimulate bone formation in states of undernutrition and low bone turnover.
Collapse
Affiliation(s)
- S K Grinspoon
- Neuroendocrine Unit, Massachusetts General Hospital, Boston 02114, USA
| | | | | | | |
Collapse
|
39
|
Katagiri M, Ohtawa T, Fukunaga M, Harada T. Evaluation of bone loss and the serum markers of bone metabolism in patients with hyperparathyroidism. Surg Today 1995; 25:598-604. [PMID: 7549270 DOI: 10.1007/bf00311432] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
Bone loss and the serum markers of bone metabolism were studied in 22 patients with primary hyperparathyroidism and 108 patients with renal hyperparathyroidism. The parameters of bone loss were bone mineral density in the distal radius and lumbar vertebrae, measured by dual energy X-ray absorptiometry, and bone mass index (sigma GS/D) and the metacarpal index, in the second metacarpal bone, measured by the digital image processing method. Alkaline phosphatase (AIP), intact osteocalcin (OC), and the carboxyterminal propeptide of type I procollagen (PICP) were measured as serum markers of bone formation, while tartrate-resistant acid phosphatase (TRACP) and the carboxyterminal pyridinoline cross-linked telopeptide of type I collagen (ICTP) were measured as serum markers of bone resorption. Bone loss and elevated markers of bone metabolism were observed both in patients with skeletal symptoms and in those without. Furthermore, the decrease in the cortical bone mass was more predominant than that of the trabecular bone. As markers of bone formation, AIP and OC seemed to be more sensitive than PICP, and as markers of bone resorption, ICTP appeared to be more sensitive than TRACP. Thus, a close correlation was observed between bone loss and the markers of bone formation and resorption.
Collapse
Affiliation(s)
- M Katagiri
- Department of Endocrine Surgery, Kawasaki Medical School, Okayama, Japan
| | | | | | | |
Collapse
|
40
|
Abstract
Most asthmatic children grow normally. However, the disease itself and the treatments used, e.g. glucocorticoids (GCs) may affect growth, especially delaying puberty. Presently, the extensive use of early anti-inflammatory therapy is changing asthma to a milder disease and the effects on growth will probably further decline. Also, the use of inhaled instead of oral GCs has minimized the risk of systemic side-effects. High doses of inhaled GCs have systemic effects, and because there are individual differences in sensitivity to GCs, growth should be monitored in every child treated with GCs. The preparations with the lowest systemic bioavailability and the lowest dose to control asthma should be used.
Collapse
Affiliation(s)
- R A Sorva
- Department of Allergic Diseases, Helsinki University Central Hospital, Finland
| | | |
Collapse
|
41
|
Blumsohn A, Hannon RA, Wrate R, Barton J, al-Dehaimi AW, Colwell A, Eastell R. Biochemical markers of bone turnover in girls during puberty. Clin Endocrinol (Oxf) 1994; 40:663-70. [PMID: 7516828 DOI: 10.1111/j.1365-2265.1994.tb03019.x] [Citation(s) in RCA: 136] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/25/2023]
Abstract
OBJECTIVE Bone turnover and the rate of bone growth increase dramatically during puberty. A number of new assays for the estimation of bone resorption and formation rates have been developed over recent years, and puberty acts as a convenient model for evaluation of these measurements. The aim of this study was to explore the interrelationships between pubertal development, biochemical markers of bone turnover, insulin-like growth factor I and oestradiol in healthy pubertal girls. SUBJECTS Ninety-one healthy girls (ages 11.6-15.5 years) were studied. All subjects were apparently healthy, and were not taking medications known to influence calcium homeostasis. Breast examination was performed to assess pubertal stage according to Tanner. The adult reference range for biochemical markers of bone turnover was obtained from concurrent studies on 42 healthy premenopausal women ranging in age between 20 and 45 years. DESIGN AND MEASUREMENTS Blood samples were obtained from subjects between 0800 and 1000 h. Urine samples were collected between 1330 and 1600 h. We measured total and bone specific alkaline phosphatase, osteocalcin, and type I procollagen carboxyterminal propeptide as markers of bone formation. Tartrate resistant acid phosphatase, carboxyterminal pyridinoline cross-linked telopeptide, creatinine corrected urinary deoxypyridinoline, immunoreactive urinary pyridinolines, and urinary galactosyl hydroxylysine were measured as markers of bone resorption. RESULTS Bone turnover as reflected by each of the markers was maximal in mid puberty (breast Tanner stages II and III) and decreased towards adult levels in late puberty (P < 0.001). However, the magnitude of the mid-pubertal increase differed between markers. In particular, the pubertal increase in levels of bone specific alkaline phosphatase, osteocalcin and urinary deoxypyridinoline were higher than the increase shown by the other markers. All markers were significantly lower after the menarche. Circulating insulin-like growth factor I and insulin like growth factor binding protein-3 were not important determinants of pubertal changes in bone turnover. In contrast, there was a significant negative correlation between oestradiol and all markers of bone formation and resorption during puberty. CONCLUSIONS The greater pubertal increase in levels of bone specific alkaline phosphatase, osteocalcin and urinary deoxypyridinoline suggests that these markers may be relatively more sensitive as indicators of skeletal health during puberty. The differences between markers may reflect differences in the bone specificity of the analytes, or differing mechanisms of production and clearance. The negative correlation between oestradiol and markers of bone resorption and formation suggests that this hormone may be responsible for the reduction in bone turnover in late puberty.
Collapse
Affiliation(s)
- A Blumsohn
- Department of Human Metabolism and Clinical Biochemistry, University of Sheffield, England
| | | | | | | | | | | | | |
Collapse
|